A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.
Iovance Biotherapeutics, Inc. IOVA
Mixed broader-coverage candidate · Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions.
On FrontierLab's discovery record since 2026-06-24 (14 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)
Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Mixed" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-09-12), not the curated Frontier signal.
⚠ Pump risk: parabolic/spike characteristics detected in the screen flags. Treat any positive grade with extra skepticism.
Key quality signals
| Revenue growth (YoY) | 34.5% |
|---|---|
| Gross margin | 116.3% |
| Gross profits / assets | 0.41 |
| Rule of 40 | -58.2 |
| Net margin | -92.7% |
| Cash runway (months) | 13.5 |
| PEG | — |
| Price / sales | 11.8 |
Quality checklist
- ✓ Revenue growth — 34.5% (pass ≥ 20%)
- ✓ Gross profits / assets — 0.41 (pass ≥ 0.33)
- ✓ Gross margin — 116.3% (pass ≥ 60%)
- ~ Cash generation
- ✗ Share dilution — 34.6%
Fundamentals — snapshot as of 2026-09-12
| Stage | Established |
|---|---|
| Share issuance (YoY) | 34.6% · heavy issuance |
| Moat | — |
| TAM | — |
| P/E (trailing) | — |
| EPS (trailing) | $-0.70 |
| Burn multiple | 0.8 |
| Gross-margin trend (pts) | 95.7 |
| Cash / assets | 0.33 |
| Net debt / EBITDA | — |
| Statements as of | Q2 FY2026 · filed 2026-08-06 |
Momentum context — a snapshot from 2026-09-12, not current
| Price at surface | $8.60 (as of 2026-09-12) |
|---|---|
| 52-week range | $1.76 – $9.36 |
| % off 52-wk high | -8.1% |
| RSI (14) | 63 |
| Relative volume | 0.9× |
Risk flags
← All broader-coverage names · Curated names → · Open the interactive screener →
Data as of 2026-09-12 (end-of-day). How grades are computed →